About US
Contact us
-
Roche nabs EU approval for Avastin for cervical cancerRoche's ($RHHBY)Avastinhas been on the market for more than a decade and boasts a long list of valuable approvals. But Roche is not sitting back the status quo, and continues to submit the drug for ne2015/4/9
-
Actavis, Ironwood mount second DTC push for GI med LinzessWith Actavis ($ACT) and Ironwood's ($IRWD) first DTC campaign for GI med Linzess, the goal was to help patients identify irritable bowel syndrome with constipation and chronic idiopathic constipation2015/4/9
-
Should 500K more young people be on statins? Guidelines say yes, JAMA reportsIf physicians followed new cholesterol guidelines for statin use, almost half a million young people in the U.S. would be prescribed a statin, aJAMA Pediatricsstudy concludes. Some 483,500 people aged2015/4/8
-
Shire could use boost from adult ADHD med to hit $10B goalShire ($SHPG) has said it's targeting $10 billion in sales by 2020, with $3 billion of that coming from its current pipeline. Now, it looks like anADHDproduct waiting in the wings could be ready in ti2015/4/8
-
Shire's Lialda, Gattex are hedge funder's latest patent targetsHedge fund manager Kyle Bass has struck out at drug patents once again. Just weeks after challenging two patents on an Acorda Therapeutics ($ACOR) drug, Bass asked the U.S. Patent and Trademark Office2015/4/7
-
J&J, Novartis lead pharma companies by market capWhich Big Pharma companies have the biggest market caps in the industry? TheMotley Foolhas a breakdown of the top 10, but we'll give you a hint: The list begins with Johnson & Johnson ($JNJ) and N2015/4/7
-
GSK shingles shot might trump Merck's Zostavax, analysts sayThough GlaxoSmithKline ($GSK) is still waiting on late-stage results from itsshinglesvaccine, HZ/su, Cowen & Co. analysts say the GSK shot may just be better than Merck'sZostavax. The deciding fac2015/4/3
-
Pfizer shutters vaccine sales business in China after Prevenar setbackAs it beefs up its vaccines business, Pfizer's ($PFE) looking to bolster revenue from the top-sellingPrevenarfamily of shots. But on that front, it's come up against a roadblock inChina--and so it's s2015/4/3
-
Celltrion revs up Remicade biosim for U.S. rollout this yearWatch out,Remicade. South Korea-basedCelltrionis gunning to launch its biosimilar version,Remsima, in the U.S. by the end of this year. In an interview withThe Wall Street Journal, Celltrion CEO Stan2015/4/2
-
UCB hands over South Asia branded drugs to Dr. Reddy's in latest slimdown planBelgium'sUCBis slimming down, selling some of its branded products in South Asia toDr. Reddy's Laboratoriesfor $128.38 million to focus on its neurology portfolio in India. The deal hands Dr. Reddy's2015/4/2